In terms of market position of foreign enterprises in China, in 2009, there were more than 200 foreign enterprises above designated size engaged in the pharmaceutical raw materials industry, accounting for more than 15% of all pharmaceutical raw materials enterprises above designated size across China. These enterprises achieved a sales revenue of more than RMB 45 billion in all, accounting for more than 25% of the total sales revenue from all pharmaceutical raw materials enterprises above designated size across China. Foreign pharmaceutical raw materials enterprises achieved a profit margin of more than 9%, higher than the industry average, and they achieved a ratio of return on assets of more than 9%, higher than the industry average.

In terms of industry profit, in 2009, enterprises above designated size in pharmaceutical raw materials industry across China achieved a profit of more than RMB 10 billion in all, a growth of more than 10% on a year-on-year basis. On average, enterprises achieved a profit margin of more than 8%. In 2009, more than 150 enterprises in this industry suffered a loss. and the loss from them added up to RMB 804.1 million.

In terms of pharmaceutical raw materials import and export, in 2010, the value of imported pharmaceutical raw materials products in China was more than USD 1 billion, and Norway, Ireland and Japan ranked top 3 as Origin of Imported Goods, imports from these top three origins added up to USD 711.8 million, accounting for more than 35% of the gross imports. In 2010, the gross export of pharmaceutical raw materials products exceeded USD 10 billion, and India, USA and Germany ranked top 3 as export destinations. Exports to these destinations added up to USD 4.4 billion, accounting for more than 35% of the gross export. Zhejiang, Jiangsu and Shandong ranked top 3 as domestic origins, exports from these origins added up to USD 5.5 billion, accounting for more than 45% of the gross export across China.